This could explain that in contrast to NRP1 inhibition [42], no significant hematologic impairment has been observed in phase III clinical trials targeting NRP2 in pulmonary fibrosis (NCT03824392, NCT04412668) [43]. This evidence concerns the gene NRP1 and pulmonary fibrosis.